Literature DB >> 7418716

Disposition and clinical pharmacokinetics of microcrystalline theophylline.

J H Jonkman, W C Berg, R Schoenmaker, R A de Zeeuw, J E Greving, N G Orie.   

Abstract

Variation in the systemic disposition of theophylline after ingestion of a new microcrystalline product (Theolair) has been investigated in 7 hospitalized patients with generalized obstructive lung disease. Disposition (absolute bioavailability) was determined by comparing in the same patients the areas under the serum concentration-time curves after a single oral dose of microcrystalline theophylline and after an intravenous infusion of aminophylline. Oral absorption appeared to be fast. The half-life of absorption was 19 +/- 9 min (mean +/- SD). Maximal serum concentrations reached after 100 +/- 30 min were found to be in a rather narrow range: 9.8 +/- 2.5 mg x 1(-1). The absolute bioavailability of the microcrystalline preparation was high and it showed only small variation: 102.7 +/- 10.2% of the dose. Relevant pharmacokinetic parameters (half-life of elimination, volume of distribution and total body clearance) were determined after both routes of administration. Individual dosage regimens required to obtain a therapeutic serum concentration were calculated for each individual patient on the basis of the observed pharmacokinetic parameters.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418716     DOI: 10.1007/bf00558452

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children.

Authors:  G Levy; R Koysooko
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

2.  Study of theophylline plasma levels after oral administration of new theophylline compounds.

Authors:  M TURNER-WARWICK
Journal:  Br Med J       Date:  1957-07-13

3.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

4.  The influence of cigarette smoking and sex on theophylline disposition.

Authors:  J R Powell; J F Thiercelin; S Vozeh; L Sansom; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1977-07

5.  Biopharmaceutics of aminophylline suppositories. II. In vitro release rate during storage.

Authors:  C J de Blaey; J J Rutten-Kingma
Journal:  Pharm Acta Helv       Date:  1977

6.  Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance.

Authors:  M W Weinberger; R A Matthay; E J Ginchansky; C A Chidsey; T L Petty
Journal:  JAMA       Date:  1976-05-10       Impact factor: 56.272

7.  Editorial: Rational use of theophylline for bronchodilatation.

Authors:  M Weinberger; S Riegelman
Journal:  N Engl J Med       Date:  1974-07-18       Impact factor: 91.245

8.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

9.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

10.  Pharmacokinetics of a microcrystalline theophylline preparation in patients with chronic obstructive airways disease.

Authors:  R K Elwood; J G Kelly; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

View more
  6 in total

1.  New method for bioavailability assessment of slow-release preparations of theophylline.

Authors:  Y Kasuya; T Ohno; N Kubota; H Takahashi; H Hirayama
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

2.  Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.

Authors:  M Lagas; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

4.  Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet.

Authors:  J H Jonkman; W C Berg; K de Vries; R A de Zeeuw; R Schoenmaker; N Grimberg
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Serum theophylline levels after use of an anhydrous crystalline theophylline suppository.

Authors:  J Aarbakke; A Høylandskjaer; O N Gamst
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation.

Authors:  J H Jonkman; G H Koëter; R Schoenmaker; K de Vries; J E Greving; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.